This life science technology company develops predictive biomarker-based platforms for the early detection and prognostics of chronic diseases. They combine longitudinal clinical data with proprietary assays and AI to evaluate aging dimensions and identify therapeutic targets. The company delivers personalized biomarker panels and AI-based algorithms to guide medical decision-making for healthy longevity.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for predicting and detecting chronic diseases often rely on late-stage symptoms, limiting the potential for early intervention and personalized treatment strategies. Traditional diagnostic approaches may not fully capture the complex interplay of factors contributing to disease onset and progression, hindering the development of effective preventative measures.
Solution
Quant Biomarkers is developing predictive biomarker-based platforms that leverage longitudinal clinical data, health records, and advanced AI algorithms to enable early detection and prognostics of chronic diseases. The company's approach combines longitudinal clinical data with in-vitro and in-vivo models, proprietary assays, and artificial intelligence to evaluate multiple dimensions of aging and identify targets for personalized medical interventions. By analyzing large clinical datasets, Quant Biomarkers aims to identify patterns that predict health outcomes and pinpoint therapeutic targets, facilitating earlier identification and intervention for health risks. The company's personalized biomarker panels are designed to guide medical decision-making and empower stakeholders in the patient ecosystem, driving sustainable, preventive, and scalable digital health solutions for healthy lifespan.
Target Audience
Quant Biomarkers primarily targets healthcare providers and medical professionals seeking advanced diagnostic tools for early disease detection, as well as pharmaceutical companies looking for new therapeutic targets.
Features
- AI-based algorithms for disease risk prediction and early interventions
- Personalized medical intervention protocols
- Tissue-specific biomarker panels for diagnostic use
- New biomarker IP for therapeutics
- Digital twin consumer application for real-time data exchange and timely interventions
- Analysis of longitudinal clinical, health records & research data to evaluate multiple dimensions of aging
- Proprietary in-vitro, in-vivo models and assays to determine pathways associated with disease onset